Download by
Scanning QR Code
Download app
Download app

大行评级 | 大和:降阿里健康(0241.HK)目标价至15港元 维持买入评级

格隆汇 ·  {{timeTz}}
格隆汇11月29日丨大和发表研究报告,引述阿里健康(0241.HK)管理层称,在现时监管环境下,用户量增长无可避免有所放缓,预期公司未来发展重点将是发掘客户长期价值。 公司预期2022下半财年至2025财年的收入年复合增长率将超过30%,其中直销业务增长速度料高于第三方业务。考虑到近期监管措施,阻碍阿里健康发展为一站式线上医疗平台的步伐,将目标价由27港元下调至15港元,维持“买入”评级。该股现报7.57港元,总市值1021.2亿港元。

This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top